Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 7.85
- Piotroski Score 4.00
- Grade Buy
- Symbol (ANNX)
- Company Annexon, Inc.
- Price $7.25
- Changes Percentage (2.26%)
- Change $0.16
- Day Low $6.94
- Day High $7.29
- Year High $8.40
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $14.00
- High Stock Price Target $14.00
- Low Stock Price Target $14.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.46
- Trailing P/E Ratio -3.93
- Forward P/E Ratio -3.93
- P/E Growth -3.93
- Net Income $-134,237,000
Income Statement
Quarterly
Annual
Latest News of ANNX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Are Analysts Bullish on Annexon, Inc. (ANNX) Right Now?
Insider Monkey compiled a list of top biotech penny stocks to buy, including Annexon, Inc. (NASDAQ:ANNX). The biotech industry is thriving, with significant growth predicted. Annexon focuses on innova...
By Yahoo! Finance | 4 months ago
